Therefore, more selective and personalized therapies incorporating drugs targeting mechanisms induced by recurrent AML mutations have been studied in various clinical trials and led to the approval of AML treatment regimens including hypomethylating agents (HMAs; azacitidine, decitabine), pro-apoptotic agents (venetoclax), FLT3 kinase inhibitors (gilteritinib, midostaurin, sorafenib, quizartinib, crenolanib), and IDH inhibitors (ivosidinib, enasidinib). The gene discussed is IDH2; the disease is acute myeloid leukemia.